 |
CLOT ConversationsAuthor: Thrombosis Canada
Unlock the latest breakthroughs in thrombosis diagnosis and management with CLOT Conversations - the must-listen podcast for healthcare professionals. Join hosts Dr Jameel Abdulrehman, a Hematologist with specialization in Thrombosis and Hemostasis at the University Health Network in Toronto, and David Airdrie, the Executive Director of Thrombosis Canada, as they delve into new research and explore the evolving field of thrombosis in 15 to 30 minute easily digestible episodes. Learn from the experts and stay ahead of the curve with Thrombosis Canada, the organization dedicated to promoting excellent patient care and improved outcomes for patients with thrombosis. Access our vast resources, tools, and programs at https://thrombosiscanada.ca and stay informed with CLOT Conversations - your go-to source for all things thrombosis. Language: en-ca Genres: Health & Fitness, Life Sciences, Medicine, Science Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
ROXI-VTE Trials Explained: Dr. Jeff Weitz on Next-Generation Thrombosis Prevention
Episode 26
Wednesday, 3 December, 2025
Send us a textIn this episode of CLOT Conversations, co-hosts Dr. Jamil Abdul-Rahman and Dr. Maha Othman have an in-depth discussion with leading thrombosis expert Dr. Jeff Weitz. Together, they unpack new findings from The Lancet on RGN-9933 and RGN-7508, two investigational factor XI inhibitors evaluated in the ROXI-VTE I and II phase-2 trials. These studies examine how targeted inhibition of factor XI may reduce post-operative venous thromboembolism with potentially lower bleeding risk than current anticoagulants.Dr. Weitz explains the distinct mechanisms of the two antibodies, the role of factor XII-mediated activation in post-operative VTE, key efficacy and safety outcomes, and how these early-phase studies set the stage for ongoing phase-2 and phase-3 trials—including ROXI-CATH, ROXI-Aspirin, and emerging AF and stroke-prevention research.This episode is essential listening for clinicians interested in the rapidly evolving landscape of anticoagulation and next-generation therapies that may offer safer options for patients undergoing orthopedic surgery and beyond.Read the full Lancet publication by clicking on the link below and explore more thrombosis resources at thrombosiscanada.ca.Become a Thrombosis Champion, be a monthly donor at https://thrombosiscanada.ca/donatehttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02097-5/abstract [Note: full access requires a subscription]Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada
